Atrium Therapeutics, Inc. (RNA) Stock Statistics & Valuation Metrics

Atrium Therapeutics, Inc. has a market cap or net worth of ―. The enterprise value is $1.99B.

Atrium Therapeutics, Inc. has 17,114,391 shares outstanding. The number of shares has decreased by -2.65% in one year.

Atrium Therapeutics, Inc.’s return on equity (ROE) is -0.41 and return on invested capital (ROIC) is -42.23%.

The current PE Ratio of Atrium Therapeutics, Inc. is ―. Atrium Therapeutics, Inc.’s PEG ratio is -0.20.

In the last 12 months, Atrium Therapeutics, Inc. had revenue of 18.75M and earned -684.63M in profits. Earnings per share was -4.97.

In the last 12 months, operating cash flow was -650.44M and capital expenditures -16.49M, giving a free cash flow of -666.93M billion.

Atrium Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Atrium Therapeutics, Inc. upcoming earnings date is Mar 3, 2026, After Close (Confirmed).

Atrium Therapeutics, Inc. as a current ratio of 9.20, with Debt / Equity ratio of 5.60%

In the past 12 months, Atrium Therapeutics, Inc. has paid 0.00 in taxes.

Atrium Therapeutics, Inc. EV to EBITDA ratio is -14.17, with an EV/FCF ratio of -14.53.

Atrium Therapeutics, Inc. has $1.70B in cash and marketable securities with $94.56M in debt, giving a net cash position of $1.60B billion.

Gross margin is -644.45%, with operating margin of -3977.30%, and net profit margin of -3650.39%.

The average price target for Atrium Therapeutics, Inc. is $25.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy